Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Lung cancer 5hmc sequencing

ABSTRACT: lung cancer 5hmc sequencing

TISSUE(S): ['blood Plasma']

SUBMITTER: Yixiang Shi

PROVIDER: OEX00020577 | NODE | 2022-10-10

REPOSITORIES: NODE

ACCESS DATA

Json Xml

Similar Datasets

Crotonylomics sequencing of human colon cancer cell lines

Project description:P53 mutation is closely associated with the occurrence and progression of colon cancer. In this project, we did crotonylomics sequencing by using human colon cancer homologous cell line pair-HCT116+/+(with wild type p53) and HCT116-/- (with null p53). Crotonylomics sequencing results showed that p53 deficiency regulated crotonylation of non-histone proteins.

2024-05-22 | PXD047258 | Pride

RNA-sequencing of non-small cell lung cancer tissue samples

Project description:Lung cancer is the deadliest cancer worldwide. In this study, we obtained RNA-sequencing data from 61 lung cancer samples. We hope that this data can improve the understanding of this disease.

2024-09-12 | GSE274975 | GEO

GNPS Systematic analyses of early-stage lung cancer by scRNA-seq and lipidomic reveals aberrant lipid metabolism as detection biomarkers

Project description:Lung cancer is the leading cause of cancer mortality and early detection is the key to improve survival. However, there are no reliable blood-based tests currently available for early-stage lung cancer diagnosis. Here, we performed single-cell RNA sequencing of early-stage lung cancer and found lipid metabolism was broadly dysregulated in different cell types and glycerophospholipid metabolism is the most significantly altered lipid metabolism-related pathway. Untargeted lipidomics were detected in an exploratory cohort of 311 participants. Through support vector machine algorithm-based and mass spectrum-based feature selection, we have identified nine lipids as the most important detection features and developed a LC-MS-based targeted assay utilizing multiple reaction monitoring. This target assay achieved 100.00% specificity on an independent validation cohort. In a hospital-based lung cancer screening cohort of 1036 participants examined by low dose CT and a prospective clinical cohort containing 109 participants, this assay reached over 90.00% sensitivity and 92.00% specificity. Accordingly, matrix-assisted laser desorption/ionization-mass spectrometry imaging assay confirmed the selected lipids were differentially expressed in early-stage lung cancer tissues in situ. Thus, this method, designated as Lung Cancer Artificial Intelligence Detector (LCAID), may be used for early detection of lung cancer or large-scale screening of high-risk populations in cancer prevention.

2021-11-05 | MSV000088324 | GNPS

Spatial transcriptomic sequencing data of human small cell lung cancer

Project description:Small cell lung cancer is a lung tumor with extremely poor prognosis, and its tumor heterogeneity and unique microenvironment remain unclear. This study aimed to reveal the early tumorigenesis and microenvironment of small cell lung cancer by performing idle transcriptomic sequencing of patients' small cell lung cancer tissues.

2026-04-02 | GSE263196 | GEO

RNA sequencing on A549 lung cancer cell line

Project description:We report the RNA sequencing on A549 lung cancer line with 40 nM TP-0903 treatment.

2020-09-30 | GSE128417 | GEO

RNA and miRNA sequencing of an IGF1R transgenic mouse model of lung cancer

Project description:RNA and miRNA sequencing of lung tumors induced by transgenic overexpression of the type-I insulin like growth factor receptor was carried out to examine the molecular changes associated with lung tumorigenesis and explore potential similarities with a collection of mouse lung cancer models and human non-small cell lung cancer.

2018-10-11 | GSE109629 | GEO

The combination human 13 gene mutation Detection kit (reversible terminal termination sequencing) complements the clinical trial

Project description:Interventions: Gold Standard:Comparison methods :(1) comparison of similar kits;(2) Sequencing method;Index test:Human 13 gene mutation Combination Detection Kit (reversible terminal termination sequencing method) Primary outcome(s): Lung and gastrointestinal tumor genes Study Design: Sequential

| 2696826 | ecrin-mdr-crc

RNA sequencing of siPI4KIIIβ-transfected lung cancer cells

Project description:RNA sequencing of siPI4KIIIβ-transfected lung cancer cells

| PRJNA493785 | ENA

RNA sequencing on A549 lung cancer cell line

Project description:RNA sequencing on A549 lung cancer cell line

| PRJNA527653 | ENA

Crotonylomics sequencing of human non small cell lung cancer cell lines

Project description:Crotonylation is a crotonyl-coenzyme A (CoA)-mediated post-translational modification best known for its roles in epigenetic regulation. Histone lysine crotonylation (Kcr) has been reported to be involved in tumor-related biological functions such as DNA damage repair and immune infiltration. Here we find that abnormal reduction of histone Kcr significantly correlates with a poor response to epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in in-house-established drug-resistant models of lung cancer cell lines, and in cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) models. The crotonyl-CoA-producing enzyme ACSS2 is the key regulator of the resistance-related change of crotonylation. Quantitative crotonylomic, transcriptomic and epigenomic analyses reveal that EGFR-TKI resistance is accompanied by reduced levels of histone 3 lysine 56 crotonylation (H3K56cr) on chromatin, which inhibits transcription of HNF1A and activates the PI3K/AKT signaling pathway. Studies of patient-derived organoids (PDOs) and resistant lung cancer CDX and PDX models treated with a novel histone decrotonylase (HDCR) inhibitor, S67, demonstrate that up-regulation of H3K56cr sensitizes cells to the effect of EGFR-TKIs. These findings uncover the role of histone Kcr in resistance to EGFR-TKIs and suggest a new combination therapy in lung cancer.

2025-09-22 | PXD053030 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data